Intas Third Party Sales 2005 S.L.
2 products tracked · names used in filings: Intas Third Party Sales 2005 S.L.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 19 Jun 2026🇪🇺 EU approval (EC decision)
Rexatilux (ranibizumab) approved in the EU
Marketing authorisation to Intas Third Party Sales 2005 S.L.; Biosimilar, Additional monitoring · source
Thu 23 Apr 2026🇪🇺 CHMP positive opinion
Rexatilux (ranibizumab): CHMP positive opinion
Intas Third Party Sales 2005 S.L.; Biosimilar, Additional monitoring · source
Mon 17 Nov 2025🇪🇺 EU approval (EC decision)
Vysribli (previously Denosumab Intas) (Vysribli) approved in the EU
Marketing authorisation to Intas Third Party Sales 2005 S.L.; Biosimilar, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Rexatilux ranibizumab | Authorised | 2026-06-19 |
| 🇪🇺 | Vysribli (previously Denosumab Intas) Vysribli | Authorised | 2025-11-17 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.